Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment

By on    Pharma Industry News  

Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment

Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its combination treatment of IMBRUVICA (ibrutinib) and rituximab for Waldenström’s macroglobulinemia (WM), a rare form of blood cancer. This latest approval expands the use of IMBRUVICA in treating WM from monotherapy to now include combination […]

Cantex Pharmaceuticals’ CX-01 receives FDA fast track designation in acute myeloid leukemia

By on    Pharma Industry News  

Cantex Pharmaceuticals’ CX-01 receives FDA fast track designation in acute myeloid leukemia

Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the US Food and Drug Administration (FDA) for its innovative acute myeloid leukemia (AML) drug, CX-01. This designation is specifically for the treatment of patients over 60 years old undergoing induction therapy for newly diagnosed AML. CX-01 is […]